Wim Jan Riedel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1083678/publications.pdf

Version: 2024-02-01

41258 54797 7,604 110 49 84 citations h-index g-index papers 112 112 112 8409 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cognitive impairment in depression: a systematic review and meta-analysis. Psychological Medicine, 2014, 44, 2029-2040.	2.7	1,394
2	The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience, 2000, 101, 485-512.	1.1	400
3	Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Molecular Psychiatry, 2007, 12, 522-543.	4.1	313
4	Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology, 1999, 141, 362-369.	1.5	248
5	Monoamine depletion in psychiatric and healthy populations: review. Molecular Psychiatry, 2003, 8, 951-973.	4.1	219
6	Serotonin and Human Cognitive Performance. Current Pharmaceutical Design, 2006, 12, 2473-2486.	0.9	218
7	Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. Journal of Psychopharmacology, 2000, 14, 21-29.	2.0	201
8	Cognitive Performance after Strenuous Physical Exercise. Perceptual and Motor Skills, 1996, 83, 479-488.	0.6	192
9	Effects of acute tryptophan depletion on memory, attention and executive functions: A systematic review. Neuroscience and Biobehavioral Reviews, 2009, 33, 926-952.	2.9	145
10	Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impairment. Journal of Neural Transmission, 2008, 115, 1301-1311.	1.4	133
11	Mood effects of 24-hour tryptophan depletion in healthy first-degree relatives of patients with affective disorders. Biological Psychiatry, 1999, 46, 489-497.	0.7	132
12	Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology, 1995, 122, 158-168.	1.5	128
13	Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacology Biochemistry and Behavior, 2011, 99, 130-145.	1.3	120
14	Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. International Journal of Neuropsychopharmacology, 2014, 17, 961-977.	1.0	119
15	Cognition following acute tryptophan depletion: difference between first-degree relatives of bipolar disorder patients and matched healthy control volunteers. Psychological Medicine, 2002, 32, 503-515.	2.7	116
16	Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Human Psychopharmacology, 2000, 15, 573-581.	0.7	109
17	Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. Journal of Psychopharmacology, 2001, 15, 173-179.	2.0	102
18	Tryptophan, mood, and cognitive function. Brain, Behavior, and Immunity, 2002, 16, 581-589.	2.0	98

#	Article	IF	CITATIONS
19	The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients. Journal of Psychopharmacology, 2005, 19, 267-275.	2.0	92
20	Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut, 2004, 53, 1794-1800.	6.1	86
21	Acute dietary tryptophan depletion impairs maintenance of "affective set" and delayed visual recognition in healthy volunteers. Psychopharmacology, 2001, 154, 319-326.	1.5	84
22	Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Science International, 2002, 128, 90-97.	1.3	84
23	Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. Neurolmage, 2010, 52, 50-54.	2.1	83
24	Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep, 2002, 25, 224-31.	0.6	83
25	The effect of hormone replacement therapy on cognitive function in elderly women. Psychoneuroendocrinology, 1999, 24, 43-68.	1.3	80
26	Dopaminergic Enhancement of Cognitive Function. Current Pharmaceutical Design, 2006, 12, 2487-2500.	0.9	78
27	Dissociable Effects of a Single Dose of Ecstasy (MDMA) on Psychomotor Skills and Attentional Performance. Journal of Psychopharmacology, 2003, 17, 379-387.	2.0	76
28	Specificity of the tryptophan depletion method. Psychopharmacology, 1999, 141, 279-286.	1.5	75
29	Response speed, contingent negative variation and P300 in Alzheimer's disease and MCI. Brain and Cognition, 2009, 69, 592-599.	0.8	75
30	Methylphenidate produces selective enhancement of declarative memory consolidation in healthy volunteers. Psychopharmacology, 2012, 221, 611-619.	1.5	73
31	Mood congruent memory bias induced by tryptophan depletion. Psychological Medicine, 2002, 32, 167-172.	2.7	71
32	Cognition Enhancers in Age-Related Cognitive Decline. Drugs and Aging, 1996, 8, 245-274.	1.3	68
33	Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. Journal of Psychopharmacology, 2005, 19, 12-20.	2.0	68
34	Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. Journal of Psychopharmacology, 2002, 16, 207-214.	2.0	67
35	40-Hz steady state response in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2011, 32, 24-30.	1.5	67
36	Sex differences in the effect of acute tryptophan depletion on declarative episodic memory: A pooled analysis of nine studies. Neuroscience and Biobehavioral Reviews, 2007, 31, 516-529.	2.9	66

#	Article	IF	Citations
37	Dissociable Hormonal, Cognitive and Mood Responses to Neuroendocrine Challenge Evidence for Receptor-Specific Serotonergic Dysregulation in Depressed Mood. Neuropsychopharmacology, 2002, 26, 358-367.	2.8	65
38	Pronounced Cognitive Deficits Following an Intravenous L-Tryptophan Challenge in First-Degree Relatives of Bipolar Patients Compared to Healthy Controls. Neuropsychopharmacology, 2003, 28, 711-719.	2.8	62
39	Effects of Acute Tryptophan Depletion on Mood and Cortisol Release in First-degree Relatives of Type I and Type II Bipolar Patients and Healthy Matched Controls. Neuropsychopharmacology, 2002, 27, 834-842.	2.8	59
40	Contingent negative variation as a dopaminergic biomarker: evidence from dose-related effects of methylphenidate. Psychopharmacology, 2011, 218, 533-542.	1.5	59
41	Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disorders, 2002, 4, 347-356.	1.1	58
42	Effects of 5-HT on Memory and the Hippocampus: Model and Data. Neuropsychopharmacology, 2006, 31, 712-720.	2.8	58
43	Lithium induced cognitive side-effects in bipolar disorder: a qualitative analysis and implications for daily practice. International Clinical Psychopharmacology, 1999, 14, 167-171.	0.9	57
44	Cholinergic drugs affect novel object recognition in rats: Relation with hippocampal EEG?. European Journal of Pharmacology, 2007, 572, 151-159.	1.7	57
45	The Influence of Soy-derived Phosphatidylserine on Cognition in Age-Associated Memory Impairment. Nutritional Neuroscience, 2001, 4, 121-134.	1.5	56
46	Caffeine Improves Cognitive Performance After Strenuous Physical Exercise. International Journal of Sports Medicine, 1999, 20, 354-361.	0.8	54
47	Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychological Medicine, 2004, 34, 103-112.	2.7	54
48	Cognitive changes after acute tryptophan depletion: what can they tell us? Psychological Medicine, 2004, 34, 3-8.	2.7	54
49	Methylphenidate Effects on Prefrontal Functioning During Attentional-Capture and Response Inhibition. Biological Psychiatry, 2012, 72, 142-149.	0.7	54
50	Modulation of the Critical Flicker Fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology, 2002, 160, 381-386.	1.5	52
51	Drug Testing in Blood: Validated Negative-Ion Chemical Ionization Gas Chromatographic–Mass Spectrometric Assay for Enantioselective Measurement of the Designer Drugs MDEA, MDMA, and MDA and Its Application to Samples from a Controlled Study with MDMA. Clinical Chemistry, 2005, 51, 1811-1822.	1.5	49
52	Cognitive Impairment in Elderly People. Drugs and Aging, 1995, 7, 459-479.	1.3	43
53	Tryptophan Modulation and Cognition. Advances in Experimental Medicine and Biology, 2003, 527, 207-213.	0.8	39
54	Memory function in women with premenstrual complaints and the effect of serotonergic stimulation by acute administration of an alpha-lactalbumin protein. Journal of Psychopharmacology, 2005, 19, 375-384.	2.0	39

#	Article	IF	CITATIONS
55	Safety of Soy-derived Phosphatidylserine in Elderly People. Nutritional Neuroscience, 2002, 5, 337-343.	1.5	38
56	Differential Residual Effects of Zaleplon and Zopiclone on Actual Driving: a Comparison with a Low Dose of Alcohol. Sleep, 2002, , .	0.6	36
57	Negative-Ion Chemical Ionization Gas Chromatography–Mass Spectrometry Assay for Enantioselective Measurement of Amphetamines in Oral Fluid: Application to a Controlled Study with MDMA and Driving Under the Influence Cases. Clinical Chemistry, 2007, 53, 702-710.	1.5	33
58	Memory impairments in humans after acute tryptophan depletion using a novel gelatin-based protein drink. Journal of Psychopharmacology, 2009, 23, 56-64.	2.0	32
59	Fatigue in Aviation: Safety Risks, Preventive Strategies and Pharmacological Interventions. Frontiers in Physiology, 2021, 12, 712628.	1.3	31
60	Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression. Psychiatry Research, 2002, 113, 29-40.	1.7	29
61	Does ketamine mimic aspects of schizophrenic speech?. Journal of Psychopharmacology, 2007, 21, 338-346.	2.0	29
62	The Effects of Acute Tryptophan Depletion on Brain Activation During Cognition and Emotional Processing in Healthy Volunteers. Current Pharmaceutical Design, 2010, 16, 1998-2011.	0.9	27
63	Cognitive domains affected by histamine H1-antagonism in humans: A literature review. Brain Research Reviews, 2010, 64, 263-282.	9.1	27
64	Auditory P300 and N100 components as intermediate phenotypes for psychotic disorder: Familial liability and reliability. Clinical Neurophysiology, 2011, 122, 1984-1990.	0.7	27
65	Residual effects of zopiclone 7.5Âmg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study. Psychopharmacology, 2014, 231, 2785-98.	1.5	27
66	Histamine H ₁ -receptor blockade in humans affects psychomotor performance but not memory. Journal of Psychopharmacology, 2008, 22, 663-672.	2.0	26
67	Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram. Psychopharmacology, 2015, 232, 1887-1897.	1.5	26
68	Avoiding and Managing Anticholinergic Effects of Antidepressants. CNS Drugs, 1995, 3, 245-259.	2.7	25
69	Caffeine improves memory performance during distraction in middle-aged, but not in young or old subjects. Human Psychopharmacology, 1998, 13, 277-284.	0.7	24
70	Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants. Psychopharmacology, 2013, 225, 903-921.	1.5	24
71	Nutrients, age and cognitive function. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 579-585.	1.3	24
72	Method development studies for repeatedly measuring anxiolytic drug effects in healthy humans. Journal of Psychopharmacology, 2010, 24, 657-666.	2.0	23

#	Article	IF	CITATIONS
73	On-the-road driving performance and driving-related skills in older untreated insomnia patients and chronic users of hypnotics. Psychopharmacology, 2014, 231, 2851-65.	1.5	22
74	Acute tryptophan depletion in depressed patients treated with a selective serotonin–noradrenalin reuptake inhibitor: Augmentation of antidepressant response?. Journal of Affective Disorders, 2005, 86, 305-311.	2.0	21
75	Human Cognition Assessment in Drug Research. Current Pharmaceutical Design, 2006, 12, 2525-2539.	0.9	21
76	Preventing cognitive decline in preclinical Alzheimer's disease. Current Opinion in Pharmacology, 2014, 14, 18-22.	1.7	21
77	Declarative Memory. Handbook of Experimental Pharmacology, 2015, 228, 215-236.	0.9	21
78	Histamine H ₁ receptor blockade predominantly impairs sensory processes in human sensorimotor performance. British Journal of Pharmacology, 2009, 157, 76-85.	2.7	20
79	Effects of Lâ€histidine depletion and Lâ€tyrosine/Lâ€phenylalanine depletion on sensory and motor processes in healthy volunteers. British Journal of Pharmacology, 2009, 157, 92-103.	2.7	19
80	Cognitive effects of methylphenidate and levodopa in healthy volunteers. European Neuropsychopharmacology, 2014, 24, 200-206.	0.3	17
81	Atypical cognitive profile in patients with depression after myocardial infarction. Journal of Affective Disorders, 2002, 70, 181-190.	2.0	16
82	Acute tryptophan depletion slows gastric emptying in females. British Journal of Nutrition, 2004, 91, 351-355.	1.2	16
83	Histamine H ₁ receptor antagonist cetirizine impairs working memory processing speed, but not episodic memory. British Journal of Pharmacology, 2010, 161, 456-466.	2.7	15
84	Effects of tyrosine/phenylalanine depletion on electrophysiological correlates of memory in healthy volunteers. Journal of Psychopharmacology, 2011, 25, 230-238.	2.0	14
85	Mechanisms of drug-induced driving impairment: a dimensional approach. Human Psychopharmacology, 1998, 13, S49-S63.	0.7	13
86	The influence of trazodone treatment on cognitive functions in outpatients with major depressive disorder. Human Psychopharmacology, 1999, 14, 499-508.	0.7	13
87	Nutrients, age and cognition. Clinical Nutrition, 2002, 21, 89-95.	2.3	13
88	Memory functions and focussed attention in middle-aged and elderly subjects are unaffected by a low, acute dose of caffeine. Journal of Nutrition, Health and Aging, 2003, 7, 301-3.	1.5	12
89	Why an M1 Antagonist Could Be a More Selective Model for Memory Impairment than Scopolamine. Frontiers in Neurology, 2016, 7, 167.	1.1	11
90	Acute tryptophan depletion in bipolar disorders; literature review and directives for further research. Acta Neuropsychiatrica, 2000, 12, 69-72.	1.0	10

#	Article	lF	Citations
91	Stress, cortisol and memory as markers of serotonergic vulnerability. Acta Neuropsychiatrica, 2002, 14, 186-191.	1.0	8
92	Memory in humans is unaffected by central H1-antagonism, while objectively and subjectively measured sedation is increased. European Neuropsychopharmacology, 2010, 20, 226-235.	0.3	8
93	Electrophysiological correlates of automatic spreading of activation in patients with psychotic disorder and first-degree relatives. International Journal of Psychophysiology, 2012, 84, 102-112.	0.5	8
94	Higher, faster, stronger: The effect of dynamic stimuli on response preparation and CNV amplitude. Behavioural Brain Research, 2013, 237, 308-312.	1.2	8
95	Mood, prolactin and cortisol responses following intravenous L-tryptophan challenge: evidence for serotonergic vulnerability in first-degree relatives of bipolar patients. International Journal of Neuropsychopharmacology, 2002, 5, 249-54.	1.0	7
96	Human electrophysiological correlates of learned irrelevance: effects of the muscarinic M1 antagonist biperiden. International Journal of Neuropsychopharmacology, 2012, 15, 1375-1385.	1.0	7
97	Ketamine and schizophrenic speech: more difference than originally reported. Journal of Psychopharmacology, 2009, 23, 111-112.	2.0	6
98	Nicotine deprivation elevates neural representation of smoking-related cues in object-sensitive visual cortex: a proof of concept study. Psychopharmacology, 2017, 234, 2375-2384.	1.5	5
99	The influence of piracetam on actual driving behaviour of elderly subjects. Human Psychopharmacology, 1998, 13, S108-S114.	0.7	4
100	Nutritional manipulation and psychiatric conditions: focus on mood and cognition. Acta Neuropsychiatrica, 2003, 15, 4-7.	1.0	2
101	The ketamine model of positive, negative and cognitive symptoms in schizophrenia: facts and frictions. Journal of Psychopharmacology, 2007, 21, 235-236.	2.0	2
102	Antihistamine induced blood oxygenation level dependent response changes related to visual processes during sensori-motor performance. Human Brain Mapping, 2014, 35, 3095-3106.	1.9	2
103	Drugs or Brains., 2019, , .		1
104	Intellectual functions and the brain: An historical perspective. Journal of Chemical Neuroanatomy, 1995, 9, 229-231.	1.0	0
105	Does a rectal barostatprocedure induce stress in healthy subjects?. Gastroenterology, 2001, 120, A398.	0.6	0
106	Reply: Pronounced Cognitive Deficits Following an Intravenous L-Tryptophan Challenge in First-degree Relatives of Bipolar Patients Compared to Healthy Controls. Neuropsychopharmacology, 2003, 28, 2214-2216.	2.8	0
107	Reply: Dissociable Hormonal, Cognitive, and Mood Responses to Neuroendocrine Challenge: Evidence for Receptor-Specific Serotonergic Dysregulation in Depressed Mood. Neuropsychopharmacology, 2003, 28, 1012-1013.	2.8	0
108	Association between serotonin transporter binding, physiological and environmental factors in healthy male subjects. NeuroImage, 2010, 52, S93-S94.	2.1	0

#	Article	IF	CITATIONS
109	S.5.3 - PSYCHOPHARMACOLOGY OF COGNITION ENHANCEMENT. Behavioural Pharmacology, 2013, 24, e6.	0.8	0
110	The Special Challenges of Developing CNS Drugs. , 2021, , 231-234.		0